Evidence map›Paper›PMID 34455723›Full record

ArticleCell journal2021

Methanolic Extract of

Hamid Aghajanzadeh, Mohsen Abdolmaleki, Mohammad Ali Ebrahimzadeh, Nazanin Mojtabavi, Tahereh Mousavi, Maryam Izad

Open access · greenAbstract read
In one paragraph

Article in Cell journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 3 citations in OpenAlex.

  1. Review
  2. Journal of traditional and complementary medicine · 2023
    Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Hamid AghajanzadehDepartment of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Mohsen AbdolmalekiDepartment of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.
Mohammad Ali EbrahimzadehPharmaceutical Sciences Research Center, School of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran.
Nazanin MojtabaviDepartment of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Tahereh MousaviDepartment of Immunology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Maryam IzadDepartment of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. Email: izadm@sina.tums.ac.ir.
Tehran University of Medical Sciences · IRIran University of Medical Sciences · IRMazandaran University of Medical Sciences · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveMATERIALS AND

methodsIn this experimental study, fifty-six C57BL\6 mice in 8 groups (G1-G8), were enrolled. Diabetes was induced by a multiple low-dose streptozotocin (MLDS) protocol and mice were daily treated with SE extract at 200 and 400 mg/kg doses, for 35 days. Fasting blood glucose was weekly measured by a glucometer. Islets insulin content was analyzed by immunohistochemistry. Percentage of CD4+, CD8+ and regulatory T cells and cytokines production levels were evaluated by flow cytometer and ELISA, respectively.

resultsThe clinical symptoms of diabetes were significantly alleviated in G2 group mice which received 400 mg/ kg SE extract. Immunohistochemistry analysis showed that the insulin content of islets increased in G2 group mice. Immunophenotyping analysis indicated that the percentage of CD4+ and CD8+ T cells in G2 group mice was significantly decreased. SE extract significantly increased the percentage of regulatory T cells. The extract in G2 and G4 groups mice significantly decreased IFN-γ and IL-17levels. The extract significantly increased IL-10 in G2 group mice.

conclusionThe protective effect of SE extract in MLDS-induced diabetes could be partly due to a decrease of CD4+ and CD8+ T cells and an increase of Treg cells resulting in an inflammation reduction in the pancreatic islets.

Indexed as

CD4+ T CellCD8+ T CellRegulatory T CellSambucu sebulusType 1 Diabetes

Identifiers

PMID34455723
PMCPMC8405075
OpenAlexW3197349784

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.